Bristol-Myers Squibb Company

Aktienanalyse zu Bristol-Myers Squibb Company (BMY)

$59.280

+2.733 (+4.61%)Zum Schluss

Loading chart…
Hoch
59.385
Eröffnung
56.810
Volumengewichteter Durchschnittskurs
58.41
Volumen
14.04M
Marktkap.
84.14B
Tief
56.580
Umsatz
820.42M
EV/EBITDA, TTM
7.55

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

www.bms.com

KI-Analyse of Bristol-Myers Squibb Company (BMY)

Kaufen

Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.

Analystenbewertungen (22)

-5.77% Abwärtspotenzial
Halten
9 Kaufen
11 Halten
2 Verkaufen
Aktuell: 59.28
Tief
37.00
Durchschnitt
55.86
Hoch
68.00

Jefferies

2026-10-12

Kursziel

$76

Kaufen

William Blair

2026-10-12

Kursziel

—

Market Perform

BofA

2026-10-09

Kursziel

$66

Kaufen

Cantor Fitzgerald

2026-10-08

Kursziel

$53

Neutral

Morgan Stanley

2026-10-07

Kursziel

$41

Untergewichten

Bewertungskennzahlen

Das aktuelle erwartete KGV von Bristol-Myers Squibb Company (BMY) beträgt 9.36, verglichen mit dem 5-Jahres-Durchschnitt von 11.38.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
11.38
Aktuelles P/E
9.36
Überbewertet
24.94
Unterbewertet
-2.19

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
10.20
Aktuelles EV/EBITDA
7.55
Überbewertet
14.39
Unterbewertet
6.01

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
2.67
Aktuelles P/S
2.38
Überbewertet
3.19
Unterbewertet
2.16

Alphio-AI-Kursszenarien für BMY

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%BMY

$44.66

Szenariopreis

B

Basis

Basis · 50%BMY

$40.66

Szenariopreis

B

Bärisch

Bärisch · 25%BMY

$35.77

Szenariopreis

Whales, die BMY halten

T

Turtle Creek Management, LLC

+ HältBMY

+21.39%

3-Monats-Rendite

C

Cbus Industry Superannuation Fund

+ HältBMY

+9.20%

3-Monats-Rendite

D

DWS Investment Management Americas, Inc.

+ HältBMY

+8.52%

3-Monats-Rendite

N

Nan Shan Life Insurance Co., Ltd.

+ HältBMY

+8.14%

3-Monats-Rendite

M

Martingale Asset Management, L.P.

+ HältBMY

+7.91%

3-Monats-Rendite

O

Osmosis Investment Management UK Limited

+ HältBMY

+7.62%

3-Monats-Rendite

Event-Zeitleiste

2026-10-12 (ET)

14:00:00

RBC Analyst Calls Bristol Myers Drug Results Positive

09:00:00

S&P 500 Futures Mixed as Oil Prices Rise

07:00:00

Bristol Myers Squibb Announces Positive ACTION-1 Trial Results

07:00:00

Bristol Myers Squibb Announces Phase 3 Trial Results for Admilparant

2026-10-08 (ET)

07:30:00

Bristol Myers Announces Positive Phase 3 Results for Zenbexus

News

BMY FAQ – beantwortet von Alphio AI

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.

22 analysts cover BMY: 9 rate it Buy, 11 Hold and 2 Sell. The average price target is 55.86.

Community

Mehr ↗
molten_vortex26.9.2026

Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT

Mehr anzeigen
RektEddy15.9.2026

$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.

Mehr anzeigen
Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten